Start here if you're new
what it is
CytoDyn develops leronlimab, a lab-made antibody tested for cancer, inflammation, and HIV.
how it gets paid
Last year Cytodyn made n/a in revenue. Oncology studies was the main engine at $0M, or 40% of sales.
what just happened
CytoDyn's latest quarter showed -$0.02 EPS, with revenue still at $0M TTM.
At a glance
B balance sheet — gets the job done, barely
55/100 earnings predictability — expect surprises
$0.00 fy2025 eps est
$0M fy2022 rev est
5.0% operating margin
xvary composite: 48/100 — below average
What they do
CytoDyn develops leronlimab, a lab-made antibody tested for cancer, inflammation, and HIV.
You do not own a broad drug basket. You own one antibody, leronlimab, and 2 shots at approval: oncology and inflammation. The company has 13 employees and a $30M funding commitment over 36 months, so the whole machine is tiny.
How they make money
n/a
annual revenue
Oncology studies
$0M
Inflammation studies
$0M
HIV legacy program
$0M
Long-acting leronlimab research
$0M
The products that matter
monoclonal antibody drug candidate
Leronlimab (PRO 140)
$0M revenue today · one clinical asset
it is the only clinical asset behind a $332M market cap and a $0M revenue base. if leronlimab fails, there is not a second business waiting to catch you.
single-asset thesis
Key numbers
$332M
market cap
You are paying $332M for a company with no reported revenue base.
$0M
ttm revenue
Zero revenue means the stock trades on trial results, not sales growth.
$30M
funding line
Yorkville's $30M commitment buys time, but it also points to future dilution.
13
employees
A 13-person team is tiny for a public biotech trying to run trials.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CYDY right now.
source: institutional data · return history unavailable
What just happened
missed estimates
CytoDyn's latest quarter showed -$0.02 EPS, with revenue still at $0M TTM.
The company still has no sales base, so the quarter matters less for growth and more for cash burn and trial progress. EDGAR shows the latest quarter at -$0.02 EPS, and consensus shows TTM revenue at $0M.
$0M
revenue
-$0.02
eps
5.0%
operating margin
the number that mattered
The important number is $0M revenue, because it tells you the stock still depends on pipeline news.
source: SEC filing and consensus data, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is leronlimab failing to advance before financing pressure forces more dilution on top of a business with $0M in revenue.
med
Going-concern risk is already explicit
Management said there is substantial doubt about continuing as a going concern. That means the survival question is not hypothetical. It is already in the filings.
With $0M in revenue, any funding gap can hit trial progress and negotiating power at the same time.
med
Dilution can outrun clinical progress
The company registered 375.9 million shares for resale after a $17.5M financing. For existing holders, that is the part that turns a scientific bet into a capital-structure problem.
Even good data matters less if the share count expands faster than the thesis improves.
med
Single-asset clinical failure
The valuation rests on one drug candidate. If leronlimab disappoints in HIV, oncology, or the regulatory path itself, the investment case does not bend. It breaks.
A $332M market cap on $0M revenue leaves very little operating business underneath the science.
med
Legal overhang adds cost to an already thin setup
At least two putative class action lawsuits have been filed against the company and former officers alleging securities law violations. Pre-revenue biotechs do not need extra distractions. This one has them.
Legal expense is one more claim on scarce capital that would otherwise fund development.
A pre-revenue company with a -70.67% return on assets and a 375.9 million-share resale shelf is exposed on both fronts that matter here: science and financing.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
Next earnings report
Scheduled for April 29, 2026. You care less about earnings and more about cash runway, financing terms, and any change in the going-concern language.
clinical
Leronlimab data flow
Any update from HIV or oncology work is a thesis event. With one core asset, there is no diversified pipeline to soften a bad readout.
financing
More equity issuance
The $17.5M raise and $30M Yorkville commitment say the funding path is still equity-heavy. Watch whether new capital arrives with even more paper attached.
coverage
Any return of analyst coverage
There are zero analysts publishing estimates right now. If that changes, you get a cleaner outside read on expectations. Until then, the market is mostly arguing with itself.
Analyst rankings
earnings predictability
55 / 100
roughly middle of the pack. in human-speak, the numbers are hard to handicap because there is no operating business to anchor them.
sell-side coverage
0 analysts
no consensus estimates, no target range, and no safety blanket. you are reading the filings directly or you are guessing.
source: institutional data
Institutional activity
institutional ownership data for CYDY is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$0
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive